-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $135

Benzinga·07/28/2026 11:06:35
語音播報
Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $125 to $135.